Table 1 Patient characteristics at the time of virological failure on initial ART (n = 84)
From: Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia
n = 84 | |
|---|---|
Age, median years (IQR) | 37 (34–44) |
Sex, n (%) | |
Men | 60 (71.4) |
Women | 24 (28.6) |
Mode of HIV transmission, n (%) | |
Injection drug use | 52 (61.9) |
Heterosexual contact | 28 (33.3) |
Male-to-male sex | 2 (2.4) |
Blood recipient | 2 (2.4) |
HCV infection, n (%) | |
anti-HCV+ | 45 (53.6) |
anti-HCV- | 39 (46.4) |
Tuberculosis, n (%) | |
History of TB | 35 (41.7) |
No history of TB | 49 (58.3) |
ART regimen at failure, n (%) | |
Zidovudine + Lamivudine + Efavirenz | 39 (46.4) |
Zidovudine + Lamivudine + Nevirapine | 14 (16.7) |
Abacavir + Lamivudine + Efavirenz | 17 (20.2) |
Abacavir + Lamivudine + Nevirapine | 3 (3.6) |
Stavudine + Lamivudine + Efavirenz | 7 (8.3) |
Stavudine + Lamivudine + Nevirapine | 2 (2.4) |
Tenofovir + Emtricitabine + Efavirenz | 2 (2.4) |
6-month adherence prior to failure, n (%) | |
<80% | 36 (42.9) |
80- < 100% | 22 (26.2) |
100% | 26 (30.9) |
Time to failure, median (IQR) | 18 (12–34) |
Viral load at failure, median copies/ml (IQR) | 23600 (8365–126000) |
Number of resistant mutations, median (IQR) | 2 (1–4) |
Drug class resistance, n (%) | |
Single class (NRTI or NNRTI) | 12 (14.3) |
Dual class (NRTI + NNRTI) | 72 (85.7) |